Epilepsy in Mitochondrial Diseases—Current State of Knowledge on Aetiology and Treatment

Mitochondrial diseases are a heterogeneous group of diseases resulting from energy deficit and reduced adenosine triphosphate (ATP) production due to impaired oxidative phosphorylation. The manifestation of mitochondrial disease is usually multi-organ. Epilepsy is one of the most common manifestations of diseases resulting from mitochondrial dysfunction, especially in children. The onset of epilepsy is associated with poor prognosis, while its treatment is very challenging, which further adversely affects the course of these disorders. Fortunately, our knowledge of mitochondrial diseases is still growing, which gives hope for patients to improve their condition in the future. The paper presents the pathophysiology, clinical picture and treatment options for epilepsy in patients with mitochondrial disease.

[1]  Dean P. Jones,et al.  Defective metabolic programming impairs early neuronal morphogenesis in neural cultures and an organoid model of Leigh syndrome , 2021, Nature Communications.

[2]  R. Mcfarland,et al.  Current and Emerging Clinical Treatment in Mitochondrial Disease , 2021, Molecular Diagnosis & Therapy.

[3]  M. Mancuso,et al.  Therapeutical Management and Drug Safety in Mitochondrial Diseases—Update 2020 , 2020, Journal of clinical medicine.

[4]  Jinze Wu,et al.  Metabolic Control of Epilepsy: A Promising Therapeutic Target for Epilepsy , 2020, Frontiers in Neurology.

[5]  F. Scaglia,et al.  Clinical trials in mitochondrial disorders, an update , 2020, Molecular Genetics and Metabolism.

[6]  S. Boyd,et al.  Diagnostic algorithm for children presenting with epilepsia partialis continua , 2020, Epilepsia.

[7]  C. Hanson,et al.  Efficacy and Safety of a Ketogenic Diet in Children and Adolescents with Refractory Epilepsy—A Review , 2020, Nutrients.

[8]  H. Prokisch,et al.  Genetics of mitochondrial diseases: Identifying mutations to help diagnosis , 2020, EBioMedicine.

[9]  T. Meitinger,et al.  Lifetime risk of autosomal recessive mitochondrial disorders calculated from genetic databases , 2020, EBioMedicine.

[10]  M. Mancuso,et al.  Safety of drug use in patients with a primary mitochondrial disease: An international Delphi‐based consensus , 2020, Journal of inherited metabolic disease.

[11]  H. Kim,et al.  Effective and safe diet therapies for Lennox-Gastaut syndrome with mitochondrial dysfunction , 2020, Therapeutic advances in neurological disorders.

[12]  R. Thomas,et al.  The mitochondrial epilepsies. , 2020, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[13]  S. Rahman,et al.  Simplifying the clinical classification of polymerase gamma (POLG) disease based on age of onset; studies using a cohort of 155 cases , 2020, Journal of inherited metabolic disease.

[14]  M. Mancuso,et al.  Mitochondrial epilepsy: a cross-sectional nationwide Italian survey , 2020, neurogenetics.

[15]  L. Elo,et al.  Integrative omics approaches provide biological and clinical insights: examples from mitochondrial diseases. , 2020, The Journal of clinical investigation.

[16]  Wei Zhang,et al.  A meta-analysis and systematic review of Leigh syndrome: clinical manifestations, respiratory chain enzyme complex deficiency, and gene mutations , 2020, Medicine.

[17]  S. Rahman.  Advances in the treatment of mitochondrial epilepsies , 2019, Epilepsy & Behavior.

[18]  S. Franceschetti,et al.  Epileptic phenotypes in children with early‐onset mitochondrial diseases , 2019, Acta neurologica Scandinavica.

[19]  T. Nicholson,et al.  Mnesic imbalance: a cognitive theory about autism spectrum disorders , 2008, Annals of General Psychiatry.

[20]  B. Pérez-Dueñas,et al.  Genetic defects of thiamine transport and metabolism: A review of clinical phenotypes, genetics, and functional studies , 2019, Journal of inherited metabolic disease.

[21]  Ji-Hoon Na,et al.  Epilepsy in Leigh Syndrome With Mitochondrial DNA Mutations , 2019, Front. Neurol..

[22]  J. Finsterer.  Pharmacotherapeutic management of epilepsy in MERRF syndrome , 2019, Expert opinion on pharmacotherapy.

[23]  J. Salas-Puig,et al.  Perampanel: A therapeutic alternative in refractory status epilepticus associated with MELAS syndrome , 2019, Epilepsy & Behavior Case Reports.

[24]  Y. Lee,et al.  Lennox-Gastaut Syndrome in Mitochondrial Disease , 2018, Yonsei medical journal.

[25]  E. Martins,et al.  Diagnosis, management, and follow-up of mitochondrial disorders in childhood: a personalized medicine in the new era of genome sequence , 2018, European Journal of Pediatrics.

[26]  P. Cooper,et al.  Ketogenic diets for drug-resistant epilepsy. , 2018, The Cochrane database of systematic reviews.

[27]  Shan Qiao,et al.  Antimyoclonic Effect of Levetiracetam and Clonazepam Combined Treatment on Myoclonic Epilepsy with Ragged-Red Fiber Syndrome with m.8344A>G Mutation , 2018, Chinese medical journal.

[28]  C. Viscomi,et al.  Towards a therapy for mitochondrial disease: an update , 2018, Biochemical Society transactions.

[29]  S. Rahman.  Mitochondrial diseases and status epilepticus , 2018, Epilepsia.

[30]  S. Cummings,et al.  Mitochondrial DNA m.3243A > G heteroplasmy affects multiple aging phenotypes and risk of mortality , 2018, Scientific Reports.

[31]  Robert W. Taylor,et al.  Clinical, biochemical and genetic spectrum of 70 patients with ACAD9 deficiency: is riboflavin supplementation effective? , 2018, Orphanet Journal of Rare Diseases.

[32]  I. Scheffer,et al.  Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group , 2018, Epilepsia open.

[33]  C. Bris,et al.  The accumulation of assembly intermediates of the mitochondrial complex I matrix arm is reduced by limiting glucose uptake in a neuronal-like model of MELAS syndrome. , 2018, Biochimica et biophysica acta. Molecular basis of disease.

[34]  Robert W. Taylor,et al.  Phenotypic heterogeneity in m.3243A>G mitochondrial disease: The role of nuclear factors , 2018, Annals of clinical and translational neurology.

[35]  Marni J. Falk,et al.  Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society , 2017, Genetics in Medicine.

[36]  S. Rahman,et al.  Recognition, investigation and management of mitochondrial disease , 2017, Archives of Disease in Childhood.

[37]  M. Kinali,et al.  Use of the Ketogenic Diet to Treat Intractable Epilepsy in Mitochondrial Disorders , 2017, Journal of clinical medicine.

[38]  D. Cao.  [Mitochondrial diseases and epilepsy]. , 2017, Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics.

[39]  J. H. Cross,et al.  Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology , 2017, Epilepsia.

[40]  Robert W Taylor,et al.  The genetics and pathology of mitochondrial disease , 2016, The Journal of pathology.

[41]  J. H. Cross,et al.  Ketogenic diet guidelines for infants with refractory epilepsy. , 2016, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[42]  J. Finsterer.  Toxicity of Antiepileptic Drugs to Mitochondria. , 2016, Handbook of experimental pharmacology.

[43]  M. Zeviani,et al.  Myoclonus epilepsy in mitochondrial disorders. , 2016, Epileptic disorders : international epilepsy journal with videotape.

[44]  R. Płoski,et al.  Difficulties in recognition of pyruvate dehydrogenase complex deficiency on the basis of clinical and biochemical features. The role of next-generation sequencing , 2016, Molecular genetics and metabolism reports.

[45]  Robert W. Taylor,et al.  Epilepsy in adults with mitochondrial disease: A cohort study , 2015, Annals of neurology.

[46]  A. Wedell,et al.  The ketogenic diet compensates for AGC1 deficiency and improves myelination , 2015, Epilepsia.

[47]  K. Aguan,et al.  Pyruvate dehydrogenase complex deficiency and its relationship with epilepsy frequency – An overview , 2015, Epilepsy Research.

[48]  F. Scaglia,et al.  MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options. , 2015, Molecular genetics and metabolism.

[49]  S. Rahman.  Pathophysiology of mitochondrial disease causing epilepsy and status epilepticus , 2015, Epilepsy & Behavior.

[50]  N. Lax,et al.  Extensive respiratory chain defects in inhibitory interneurones in patients with mitochondrial disease , 2015, Neuropathology and applied neurobiology.

[51]  Marni J. Falk,et al.  Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society , 2014, Genetics in Medicine.

[52]  N. Nomura,et al.  Clinical and biochemical characterization of 3-hydroxyisobutyryl-CoA hydrolase (HIBCH) deficiency that causes Leigh-like disease and ketoacidosis , 2014, Molecular genetics and metabolism reports.

[53]  M. Koenig,et al.  Seizure semiology and EEG findings in mitochondrial diseases , 2014, Epilepsia.

[54]  Peter Herman,et al.  Mitochondrial Calcium Uptake Capacity Modulates Neocortical Excitability , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[55]  D. Hardie,et al.  AMPK: a nutrient and energy sensor that maintains energy homeostasis , 2012, Nature Reviews Molecular Cell Biology.

[56]  Hsiu-Fen Lee,et al.  Epileptic seizures in infants and children with mitochondrial diseases. , 2011, Pediatric neurology.

[57]  V. Tiranti,et al.  Combined treatment with oral metronidazole and N-acetylcysteine is effective in ethylmalonic encephalopathy , 2010, Nature Medicine.

[58]  A. Munnich,et al.  Epileptic phenotypes in children with respiratory chain disorders , 2010, Epilepsia.

[59]  M. Orešič,et al.  Ketogenic diet slows down mitochondrial myopathy progression in mice. , 2010, Human molecular genetics.

[60]  R. Naviaux,et al.  POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders , 2010, Seizure.

[61]  Hoon-Chul Kang,et al.  Mitochondrial respiratory chain defects: Underlying etiology in various epileptic conditions , 2008, Epilepsia.

[62]  I. Valencia,et al.  Epilepsy and Respiratory Chain Defects in Children with Mitochondrial Encephalopathies , 2008, Neuropediatrics.

[63]  T. Matsuishi,et al.  MELAS and L-arginine therapy. , 2007, Mitochondrion.

[64]  M. Zeviani,et al.  The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases. , 2006, Brain : a journal of neurology.

[65]  A. Ormazabal,et al.  Cerebral folate deficiency and leukoencephalopathy caused by a mitochondrial DNA deletion , 2006, Annals of neurology.

[66]  E. Schon,et al.  Ketogenic treatment reduces deleted mitochondrial DNAs in cultured human cells , 2004, Annals of neurology.

[67]  M. Fukuda,et al.  Neuronal hyperexcitability in stroke-like episodes of MELAS syndrome , 2002, Neurology.

[68]  P. Chinnery,et al.  Diagnostic Approach to Mitochondrial Diseases , 2019, Diagnosis and Management of Mitochondrial Disorders.

[69]  J. Shuster,et al.  The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients. , 2012, Molecular genetics and metabolism.